We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Comparative Analysis of Survivin Expression in Untreated and Relapsed Canine Lymphoma.
- Authors
Bebhun, R. B.; Lana, S. E.; Ehrhart, E. J.; Charles, J. B.; Thamm, D. H.
- Abstract
Background: Survivin, a member of the inhibitor of apoptosis protein family, has a dual role in tumor cell proliferative and antiapoptotic pathways. Survivin expression has been shown to be a negative prognostic factor in several cancers of humans, including B-cell non-Hodgkin's lymphoma. Hypotheses: High survivin expression will be a negative prognostic factor in dogs with lymphoma (LSA) treated with chemotherapy. In addition, survivin expression will be upregulated in relapsed canine LSA when compared with patient-matched, pretreatment biopsies. Animals: Thirty-one client-owned dogs with stage IIIa or IVa LSA. Methods: Retrospective evaluation of survivin immunoreactivity was performed on pretreatment lymph node biopsies and patient-matched samples obtained from dogs at relapse after being treated with an abbreviated CHOP-based protocol. Results: In this population of dogs presenting with stage IIIa or IVa B-cell LSA, those dogs that had high survivin immunoreactivity scores had a significantly ( P < .01, hazard ratio = 0.30) shorter median disease-free interval than did dogs with low survivin immunoreactivity scores (171 days versus 321 days, respectively). Survivin immunoreactivity was not significantly different in relapsed canine LSA when compared with patient-matched, pretreatment biopsies. Conclusions and Clinical Importance: Survivin expression is a negative prognostic factor that can predict early treatment failure of dogs that present with stage IIIa or IVa, B-cell LSA when treated with a CHOP-based protocol.
- Publication
Journal of Veterinary Internal Medicine, 2008, Vol 22, Issue 4, p989
- ISSN
0891-6640
- Publication type
Academic Journal
- DOI
10.1111/j.1939-1676.2008.0143.x